Current Oncology Reports

, Volume 14, Issue 5, pp 441–448

Mucosal Melanoma: Pathogenesis, Clinical Behavior, and Management

Authors

  • Michael A. Postow
    • Department of MedicineWeill-Cornell Medical College, Memorial Sloan-Kettering Cancer Center
  • Omid Hamid
    • Melanoma Center, Translational Research Institute & ImmunotherapyThe Angeles Clinic and Research Institute
    • Department of MedicineWeill-Cornell Medical College, Memorial Sloan-Kettering Cancer Center
    • Memorial Sloan-Kettering Cancer Center
Melanoma (K Margolin, Section Editor)

DOI: 10.1007/s11912-012-0244-x

Cite this article as:
Postow, M.A., Hamid, O. & Carvajal, R.D. Curr Oncol Rep (2012) 14: 441. doi:10.1007/s11912-012-0244-x

Abstract

Mucosal melanoma represents a rare subtype of melanoma with distinct biological, clinical, and management considerations. Knowledge regarding optimal treatment strategies for mucosal melanoma is limited and based primarily upon small case series and single-institution, retrospective analyses. Surgery remains the standard of care for loco-regional management, but the common presence of multifocal disease and the high rate of distant recurrence should be considered before pursuing aggressive surgical interventions associated with inherent significant morbidity. The role of sentinel lymph node biopsy and lymph node dissection remains unclear. Radiotherapy has not been shown to improve overall survival but may reduce the rate of local recurrence. Significant advances in the treatment of metastatic disease have been made with novel immunotherapeutic agents, the discovery of KIT and BRAF mutations and the development of targeted agents that inhibit these oncogenic pathways.

Keywords

Mucosal melanomac-KITHead and neck melanomaAnorectal melanomaVulvovaginal melanomaIpilimumabVemurafenibImatinib

Copyright information

© Springer Science+Business Media, LLC 2012